Simon-Kucher published an article examining how biotechs weigh access, speed, investment, and control to choose the right path to commercialization and make limited resources work harder.

Simon-Kucher is a global consultancy with more than 2,200 employees in 30+ countries. As a trusted commercial advisor focused on unlocking better growth, we combine deep consulting expertise, growth specialization, and technology to scale lasting impact. We optimize every lever of commercial strategy – product, pricing, innovation, marketing, and sales – based on what customers want and value. With over 40 years of monetization experience, we are recognized as the world’s leading commercial growth and pricing specialist. (Legal notice: https://www.simon-kucher.com/en/legal-notice) -- Terms of use: Simon-Kucher's official LinkedIn page is run by Simon-Kucher & Partners Strategy & Marketing Consultants (SK). This is a public forum and we welcome your comments, thoughts and insights. However, all posts are regularly monitored and SK will remove, hide and/or delete any that are found to be abusive or deemed inappropriate for this page for whatever reason, including content that is deemed none compliant with LinkedIn’s User Agreement (https://www.linkedin.com/legal/user-agreement). This includes the banning and reporting of users who are deemed to be non compliant with the above expectations of Simon-Kucher. All comments, visuals, links to other digital pages and other type of material posted by followers on this site ("User Content") do not necessarily reflect the opinions or values of SK, its employees, partners or affiliates. SK does not represent or warrant the accuracy of any statement or product claims made here, is not responsible for any User Content on this site and does not endorse any opinions expressed on this page.